Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer

1. _{The Keenan Research Center for Biomedical Sciences at the Li Ka Shing Knowledge Institute and Department of Laboratory Medicine, St. Michael’s Hospital, Toronto, Canada} 2. _{Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada} 3. _{Department of Pharmacy, School of Health Sciences, University of Patras, Rion-Patras, Greece}

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Kallikrein-related peptidase 5 (KLK5) displays aberrant expression in cancer. Recently, we showed KLK5 reconstitution in breast cancer cell lines suppresses malignancy. Present study aims to investigate the functional KLK5 mediated miRNA network on breast cancer progression, molecular subtype and survival.

28 miRNAs were up-regulated and 62 miRNAs were down-regulated upon KLK5 expression. Extracellular matrix (ECM) molecules and cell-adhesion pathways were the most significant KLK5-induced miRNA-mediated regulatory targets. Validation from The Cancer Genome Atlas (TCGA) database indicated KLK5 was specifically down-regulated in luminal B and basal-like breast cancer subtypes. There was a correlation between KLK5, miRNAs and their downstream ECM gene targets. Long-term patient survival correlated with dysregulation of KLK5 and interacting ECM target genes. It suggests biological differences between breast cancer molecular subtypes, patient survival, and their propensity for invasion and metastasis can be explained in part by altered miRNA networks induced by KLK5 dysregulation.

We provide the first evidence that KLK5 can affect miRNA networks, which regulate MMPs and other novel ECM targets and a new compelling hypothesis of interplay between serine proteases and miRNAs. We developed a combined KLK5-(ITGB1+COL12A1) predictive score for recurrence-free survival that could be exploited in clinical applications.

INTRODUCTION

Breast cancer is the most common cancer and the leading cause of death of cancer for women [1]. In addition to the histological subtypes, it is now clear that distinct “biological” and molecular subtypes associate with vastly different clinical outcomes [2, 3]. An understanding of the mechanisms that influence tumor behavior is key to an era of personalized medicine [4].

The human kallikrein-related peptidases (KLK) are expressed in various tissues including breast, ovary, prostate, and kidney [5]. They have been found to be dysregulated in different cancers [6]. KLK5 has been reported to be dysregulated in breast cancer with its over-expression is indicative of good prognosis

[7, 8, 9, 10]. We recently showed that KLK5 exerts tumour

suppressive effects by inhibiting the mevalonate pathway in breast cancer cells, thus, inhibiting the activation of signaling oncoproteins due to inhibited prenylation [11]. Nonetheless, other molecular mechanisms by which KLK5 influences tumour behaviour are yet to be elucidated.

MicroRNAs (miRNAs) are 19-25-nucleotide, non-coding RNAs, which negatively regulate gene expression post-transcriptionally [12]. miRNAs are dysregulated in many cancers and, depending on their target, can act as oncogenes or tumor suppressors [13]. Recent literature indicate the presence of miRNA networks that can synergistically control cellular pathways [14]. The regulation of KLK by miRNAs was proposed recently [15, 16], and demonstrated in kidney, prostate and ovarian cancers ^{[17, 18, 19]. However, the effect of KLKs on miRNA} expression has not been elucidated.

Therefore, we investigated KLK5-miRNA networks of interaction and their potential effects on the pathogenesis of breast cancer. We show for the first time that KLK5 can affect breast cancer pathogenesis through miRNA-mediated pathways. We analyzed the role of miRNA as downstream effectors of KLK5 through identification of a network of miRNAs that are dysregulated in response to altering KLK5 expression. Target prediction, pathway analyses, experimental validation, and clinical data analyses indicate that KLK5 regulates miRNA networks involved in divergent and convergent miRNA pathways that regulate extracellular matrix (ECM) molecules. In addition, we provide evidence that KLK5 can affect the miRNA biogenesis machinery. Importantly, our clinical data validation demonstrates that the miRNA-KLK-ECM interaction matrix not only contributes to the different phenotypic and molecular sub-groups of breast cancer but is also likely to be of benefit for prognostic and therapeutic intervention.

RESULTS

KLK5 affects miRNA expression

The MDA-MB-231 invasive breast cancer cell line was stably transfected with KLK5 cDNA to express physiological levels of the KLK5 mRNA and protein. Two clones were used for analysis. We compared the expression levels of 754 human miRNAs between the KLK5-transfected cells and their parental and vector-transfected (mock) counterparts. We identified 28 miRNAs that were up-regulated and 62 miRNAs that were down-regulated by more than 0.5-fold upon KLK5 expression. These included up-regulated miR-183-5p, miR-206, miR-181-c, and miR-19a and down-regulated miR-935, miR-519a-5p, and miR-23b-5p. The top 10 up- and down-regulated miRNAs are shown in Table 1.Overall, there was a significant trend of miRNA down-regulation with KLK5 expression with a mean of -30.67 fold reduction (SD = 36.13, SEM = 2.950). 10% Percentile = -86.72 fold reduction; 90% Percentile= +3.602 fold increase (Figure 1).

Target prediction and pathway analyses

The most significant predicted gene targets of the top dysregulated miRNAs are shown in Table 2. We experimentally validated the correlation between the expression of these targets and their targeting miRNAs by comparing gene expression profiles before and after KLK5 transfection using microarray analysis. As shown in Table 2, many of these genes were found to have an inverse correlation in expression changes with their targeting miRNA upon KLK5 transfection. In order to elucidate the involvement of these targets in cancer pathogenesis, we performed pathway and gene enrichment analysis for all targets (Supplementary Table 1 and Supplementary Table 2). KLK5 expression induced down-regulation of a set of miRNAs identified as enriched in the MAPK miR-1255b-5p-14.962 NAV1 2.28 FILIP1L 3.69 miR-650-12.622 TNRC6B 1.48 ZFHX4 1.64 TRAF1 1.69 SORL1 1.83 SCD 4.99 miR-342-3p-10.714 DLGAP4 1.59 ZFHX4 1.64 SORL1 1.83

*

Assessed by qRT-PCR screening

**

Assessed by Illumina Chip signaling, apoptosis and p53 pathways. It also caused up-regulation of a set of miRNAs that is associated with GnRH signaling, and ECM-receptor interaction pathways.

Extracellular matrix (ECM) gene expression changes were among the most significantly affected in our prediction analysis. We identified a miRNA network with convergent (where multiple miRNAs can target the same gene) and divergent (where the same miRNA can target multiple genes along the same pathway) properties (Figure 2). To validate the proposed miRNA-mediated effect of KLK5 on ECM, an ECM profiling array was conducted which indicated significant expression alterations in ECM pathway genes in KLK5-transfectants (Figure 3). These changes included downregulation of cell to matrix adhesion molecules such as reduced integrin (ITG) expression including integrin beta-1 (ITGB1) (Figure 3A); decreased expression of basement membrane constituents (Figure 3B); reduced collagen and structural constituents expression (Figure 3C); and lower ECM proteases expression (Figure 3D).

miRNA-ECM interactions in MDA-MB-231 cell lines

We next investigated the effect of KLK5-induced miRNAs on ECM. We were able to identify several statistically significant conserved miRNA binding sites in the 3’ UTR of the ITGB1 gene as well as other ECM genes, as shown in Supplementary Table 3.

In order to experimentally validate the KLK5/miR-183-5p/ITGB1 interaction, we compared miR-183-5p and ITGB1 mRNA expression in KLK5 stably transfected MDA-MB-231 cells compared to controls. Upon KLK5 transfection, there was significant elevation of miR-183-5p levels (Figure 4A). In the same time, KLK5 also resulted in significant (3-fold) reduction of ITGB1expression compared to mock cells (Figure 4B).

We hypothesized that the effect of KLK5 on ITGB1 expression is mediated through the up-regulation of miR-183-5p. In order to test this hypothesis, a miR-183-5p inhibitor was transfected into stable KLK5 expressing cells. Transfection with the inhibitor of miR-183-5p resulted in reversal of the inhibition of miR-183-5p on ITGB1 gene expression in a dose-dependent manner (Figure 4C).

Mechanisms underlying the KLK5 effect on miRNAs

To further explore the putative mechanisms by which KLK5 can affect miRNA expression and function, we examined the expression of a number of molecules involved in miRNA biogenesis (Figure 4D). We demonstrate that KLK5 re-expression down-regulates multiple key members of the miRNA biogenesis machinery including the RNAse III-type protein and Drosha, which is involved in the initial steps of the miRNA biogenesis pathway. Furthermore, KLK5 was demonstrated to reduce Exportin5 expression, which will lead to inhibited export of miRNAs from the nucleus to the cytoplasm. Finally, KLK5 was also found to reduce the mRNA levels of RNAse III enzyme Dicer and the Argonaute (Ago) proteins (1 and 2). Dicer and Argonaute are vital for miRNA maturation for the binding of the miRNA to the mRNA complex of the target, and silencing of the mRNA through RISC.

These results indicate that the effect of KLK5 on miRNAs is mediated in part by reducing the expression of the genes involved in miRNA biogenesis. This matches the trend towards global down-regulation of miRNAs. Interestingly, using miRWALK analysis, we were able to identify a number of statistically significant miRNA response elements in the 3’ UTR of the genes coding for the enzymes involved in miRNA biogenesis, as shown in Supplementary Table 3. Some of these miRNA sites have been validated previously including miR-183: DICER1, AGO1 (EIF2C1) [20], AGO2 (EIF2C2) ^{[21, 22, 23]}; and miR-206: Exportin5 [24, 25]. Taken together, out data points out that KLK5 re-expression in non-expressing breast cancer cells results in up-regulation of specific miRNAs which can target critical molecules involved in miRNA biogenesis with subsequent global down-regulation of miRNA expression.

Association of KLK5 and miR-183 with biological characteristics of breast cancer

In order to assess potential clinical implications of the KLK5-miR-183-5p axis in breast cancer behavior, we examined the expression of these molecules in breast cancer tissues from patients through the TCGA databases. A sub-set of patients were recovered with changes in KLK5, miR-183-5p and ITGB1 expression of at least 1 z-score. Higher expression of KLK5 correlated with higher levels of miR-183-5p, lower ITGB1 expression, and a basal-like breast cancer subtype (Figure 5A). These findings further confirm our proposed KLK5-miR-183-5p-ITGB1 axis of interaction. Lower expression of KLK5 and miR-183-5p was correlated with higher ITGB1 expression and a luminal A or B breast cancer subtype in these patients. Interestingly, demonstrated metastasis was only found in the two patients with the lowest expression of KLK5 and miR-183-5p, and the highest ITGB1 expression (Supplementary Figure 1).

Potential prognostic significance of KLK5

Examination of survival data in our dataset (IlluminaHiSeq, n=1106) demonstrated higher long-term overall survival in patients with basal-like breast cancer, compared with luminal B and Her-2 enriched, as expected. Overall survival was significantly shorter in association with lower KLK5 expression levels (Figure 5B). Moreover, we developed a predictive score KLK5-(ITGB1+COL12A1) which demonstrated patients with the highest scores had improved long-term recurrence free survival (RFS) compared with patients with the lowest scores (IlluminaHiSeq, n=1106) (Figure 5C).

Clinical Validation of KLK5-miRNA axis in breast cancer subtypes

Analysis of TCGA data validated the link between the identified KLK5-miRNA axis and breast cancer subtypes. Using over 500-patient samples comprised of 80 basal-like, 128 luminal B, 231 luminal A, and 57 Her2 overexpressing breast cancers, we found that KLK5 expression was significantly reduced in the luminal B subtype as compared with basal-like breast cancers (Figure 6A). Luminal B is known to have aggressive behavior including invasion and metastasis. Expression of miRNA-183 positively correlated to KLK5 expression, with the highest miR-183 levels in basal-like breast cancers (Figure 6A). This further supports that KLK5 expression is correlated to miRNA network regulation. Also, miR-206 and miR-19a were also demonstrated to have a positive correlation with KLK5 levels with elevated expression in basal-like breast cancers, whereas miR-10b expression was inversely correlated to KLK5 expression with the lowest levels in patients with basal-like breast cancers (Figure 6A). To further confirm our data, we visualized a second clinical dataset (IlluminaHiSeq, n=1106), which demonstrated low miR-10b in basal-subtypes (Supplementary Figure 2). Interestingly, miR-19a expression positively correlated with KLK5 expression with higher expression in basal-like subtypes. Other highly up-regulated or down-regulated miRNA data was unfortunately not available to assess visually with this microarray data set. Taken together, KLK5 expression and its effects on miRNA networks and the ECM molecule expression may provide a contributing mechanism to luminal B subtypes’ aggressive behavior.

Clinical Validation of miRNA-ECM Targets in breast cancer subtypes

In order to validate miRNA network regulation of ECM genes, we assayed the TCGA database. Ezrin, a validated target of miR-183 was found to be negatively correlated to KLK5 expression with lower expression in basal-like and higher expression in luminal B subtypes (Figure 6B). Also, a number of other targets of the up-regulated miRNAs, including ITGB5, COL12A1, and COL24A1 expression were found to be lower in basal-like compared to the other subtypes (Figure 6B). The correlation between ITGB1 and KLK5 expression was also noted in a subset of patients (Figure 5A), but was not significant in the larger cohort of patients, indicating the presence of other mechanisms that control ITGB1 expression.

To further confirm our data, we visualized a second clinical dataset (IlluminaHiSeq, n=1106), which demonstrated higher expression of KLK5 in normal tissue, with a reduction of expression in metastatic tissues (Figure 6C). Interestingly, expression of KLK5 was high in basal-like and normal-like breast cancer subtypes with a reduction in levels in luminal B. There was reduced expression in normal tissue and basal subtypes with higher expression in luminal (ER+) and Her-2 subtypes for ITGB5, EZR, COL12A1, and COL24A1. Changes in ITGB1 expression were not significant.

We further validated the expression of other ECM genes in the different subtypes through the TCGA database. MMP 2, 11, 13negatively correlated to KLK5 expression with reduced expression in basal-like and elevated levels in luminal B subtypes (Supplementary Figure 3). MMP3 expression did not show significant changes. We also visualized a second clinical dataset (IlluminaHiSeq by RNASeq, n=1106), which demonstrated lower expression of all MMPs examined with the exception of MMP2 in normal tissue. Interestingly, expression of MMPs 3, 11, and 13 were negatively correlated to KLK5 expression with the highest expression levels in the Her-2 and luminal groups (Supplementary Figure 4).

Proposed model for a KLK5-miRNA-ECM network in breast cancer

Our data demonstrates that KLK5 expression affects the expression of a network of interacting miRNAs. These miRNA networks were found to be enriched in ECM molecule targets. We propose a model in which KLK5 not only regulates ECM and cell adhesion directly post-translationally through its proteolyitc activity, as previously reported [26], but also affects the level of these proteins through miRNA-mediated pathway(s). KLK5 over-expression results in up-regulation of a subset of miRNAs and also to down-regulation of another miRNA group. miRNA under-expression can be mediated through affecting critical enzymes involved in miRNA biogenesis which in turn can be mediated through the up-regulation of a number of miRNAs that are known to target these enzymes. These pathways merge to have an amplified downstream impact on ECM regulation, breast cancer phenotype and metastatic potential (Figure 7).

DISCUSSION

In line with recent literature documenting the critical involvement of miRNAs in oncogenesis and their role in breast cancer progression [27], our results add a new dimension by demonstrating a crosstalk between proteolysis and miRNAs, and a potential regulatory role of KLK5 in controlling the expression of miRNA networks which affect target ECM molecule interactions.

The potential utility of KLK5 as a cancer biomarker has been reported. Reduced expression of KLK5 has been observed in breast cancers[9, 28], and in malignant compared to benign breast tissue [29]. KLK5 is also found to be down-regulated in pancreatic [30], prostate [31], lung [32], testicular [33], and renal cancers [34], pointing to a tumor suppressor function. We demonstrated that KLK5, and a combined KLK5 scoring that includes ECM genes can predict breast cancer patient survival as well the differentiating between breast cancer subtypes.

Luminal breast cancers are highly correlated to estrogen receptor (ER) positive expression (82% of luminal B and 87% luminal A versus 10% ER positivity in basal-like and 20% positivity in Her-2 type [35]. Reduced KLK5 expression was previously found to correlate with ER-negative breast cancers which are mainly composed of the subtypes luminal A and B. Of 102 samples, 77% patients which were ER-positive were also KLK5-negative [29]. This is in keeping with our findings where the lowest KLK5 expression was in the ER+ luminal B subtype compared to other subtypes.

Reduced KLK5 expression as found in luminal B and Her-2 subtypes corresponded to reduced overall survival. Similarly, the lowest composite scores of KLK5-ITGB1-COL12A1 had the poorest RFS as compared to the highest scores. Our hypothesis and data is, therefore, in line with the U133A tumor compendium dataset of 1,340 breast cancer patients which demonstrated luminal B has the worst prognosis in terms of distant metastasis-free survival over 25 years, followed by luminal A, Her-2 and basal-like [36].

We also provide evidence that the KLK5-miRNA-ECM axis could be related to the biological differences between the breast cancer subtypes. KLK5 affected the expression of a network of miRNAs, which are known to inhibit invasion and metastasis in breast cancer. We confirmed these results both experimentally by reconstituting KLK5 expression in cell lines [37], and clinically by showing a correlation between KLK5 expression and a number of these miRNAs in high metastatic potential cancers such as luminal B and Her-2 enriched subtypes. Up-regulated miRNAs included miR-19a, which is known to inhibit tissue factor. Tissue factor regulates tumor angiogenesis, metastasis, and is selectively expressed in highly invasive cancer cells [38]. In the study by Tavazoie et al., miR-335 was demonstrated to inhibit metastasis and regulate genes associated with risk of distal metastasis. Furthermore, expression of miR-335 is lost in the majority of primary breast tumors from patients who relapse [39].

We also show that miR-10b, a pro-metastatic miRNA, was reduced upon KLK5 overexpression, and was also lower in the basal-like subtype that has higher KLK5 expression. miR-10b was demonstrated to be highly expressed in about 50% of metastatic tumors [40]. In addition, miR-10b is over-expressed by 50-fold in metastatic MDA-MB-231 cell lines, in comparison with non-metastatic MCF7 cells [41]. Our data suggest that miR-10b can be a downstream effector target of KLK5.

KLK5 demonstrated higher expression in the basal-like subtype, with positive correlation with miR-206 and miR-183-5p. miR-206 is known to be down-regulated in ER-positive breast cancers, and it inhibits cell growth in a dose-dependent manner[42]. Literature also describes miR-206 as a tumor suppressor [40]. In an analysis comparing invasive to less invasive cell lines, miR-183 was demonstrated to be down-regulated in invasive cell lines including MDA-MB-231 [43]. Furthermore, miR-183-5p was significantly down-regulated in 8 of 11 human breast cancer stem cells [44]. It has also been demonstrated that over-expression of miR-183 inhibits migration of cancer cells through its action on VIL2 / Ezrin [45]. In other cancers, miR-183 has also been demonstrated to reduce metastasis through its action on Ezrin [46].

In order for cancer cells to metastasize, they must undergo invasion, migration and attachment to a new tissue. Integrins play an important role in these processes [47]. Antagonists of several integrins (α5β1, αvβ3 and αvβ5) are currently under evaluation in clinical trials to determine their potential as therapeutics for cancer and other diseases [48]. MDA-MB-231 breast cancer cell lines express high levels of ITGA2 / ITGB1, ITGA3 / ITGB1, ITGA5 / ITGB1, ITGAV / ITGB3 integrins, compared to MCF-7, T47D, and ZR75-1 breast cancer cells [49]. ITGB1 was previously shown to be targeted by miR-183-5p. miR-183 significantly decreased the expression of ITGB1 as measured by Western blot and immunocytochemistry [50]. Furthermore Li et al. demonstrated that miR-183 transfection led to a significant decrease in the cellular invasion and migration capacities of HeLa cells [50]. Blocking ITGB1 binding activity has been shown to revert the transformed phenotype of human breast cancer cells [51, 52]. Furthermore, targeted disruption of ITGB1 in a transgenic mouse model of human breast cancer inhibited both initiation and maintenance of mammary tumor growth [53]. COL12A1 has been shown to be a statistically significant representation of myoepithelial types [54], and loss of myoepithelial function is a key step in breast cancer progression[55].

Proteases and their inhibitors play important roles in tissue invasion and cell migration. KLK5 seems to play important roles in cell-to-matrix adhesions. Previous reports identified several ECM molecules including collagens type I, II, III, and IV, fibronectin, and laminins as potential KLK5 targets [26]. KLK5 has also been demonstrated to interact with α2-integrins, resulting in suppression of invasion of cancer through ectodomain regulation [30]. We reported that re-expression of KLK5 results in suppressed motility of MDA-MB-231 cells consistent with the observed down-regulation of the embryonic transcription factor SNAIL1 and reduced expression and proteolytic activity of MMP9[11].Furthermore, KLK5 inhibits RhoA signaling by suppressing cholesterol/isoprenoid biosynthesis [11], which could account for the inhibition of MMP-9[56]. Here, EMC array analysis confirmed the anti-correlation of KLK5 and MMP9, which was found to be the most highly suppressed protease upon KLK5 re-expression. An intriguing novel finding of our present analysis is the inverse correlation of KLK5 and ezrin, a membrane cytoskeleton linker protein, which has been shown to increase tumor motility and invasion, and is considered key to the metastatic process [57].

KLKs and MMPs have been demonstrated to regulate each other post-translationally by limited proteolysis ^{[58, 59, 60]. We show here that KLKs and MMPs} may regulate each other also post-transcriptionally through regulatory miRNA networks. MMPs have been demonstrated to have a significant role in breast cancer invasion and metastasis due to their ability to degrade extracellular matrix proteins [61]. Here, we provide evidence that KLK5 may regulate MMPs through miRNA networks, and MMP-2, -11, -13 and their expression is lower in basal-like subtypes. It has been well-documented that cellular and ECM matrix interactions regulate downstream cellular pathways including miRNA networks, cell survival and apoptosis through pathways such as p53 [62, 63]. We postulate that the protease activity of KLK5 may affect a miRNA network indirectly through its effect on the ECM and subsequent down-stream signaling pathways, which can affect transcription and miRNA processing.

In conclusion, we provide evidence for KLK5-mediated regulation of a network of miRNAs in breast cancer, with consequences on downstream ECM regulatory target gene expression linked to metastatic potential, patient survival and the molecular subtype of breast cancers with potential clinical applications.

MATERIALS AND METHODS

Cell culture and plasmid transfection

The MDA-MB-231 cell line was obtained from the American Type Culture Collection. Cells were cultured as described [11]. The cDNA encoding preproKLK5 was amplified by PCR from a full-length KLK5 cDNA using gene-specific primers and cloned into the pcDNA3.1 (+) vector (Invitrogen, Carlsbad CA). Plasmids were purified (Qiagen, Valencia, CA) and confirmed by DNA sequencing (ACGT, Toronto, Canada). Stably transfected MDA-MB-231 cells were selected with G418.

miRNA and gene expression profiling

Illumina chip assayed mRNA data was obtained as described [11]. Expression of 754 miRNAs was compared before and after KLK5 transfection using TaqMan® Low Density Arrays. RNA extraction was carried out using the miRNeasy (Qiagen). The integrity and concentration of total RNA was quantified using a bioanalyzer (Agilent). cDNA was synthesized from 200ng of total RNA using TaqMan® MicroRNA Reverse Transcription and the Megaplex™ RT Primers (Life Technologies) as per the manufacturer’s instructions. 200ng total RNA was mixed with 10X Megaplex RT Primers, 100mM dNTPs, 10X RT Buffer, 25mM MgCl₂, and 20U/µL RNase Inhibitor. Samples underwent 40 cycles of 16°C for 2 mins, 42°C for 1 min and 50°C for 1 sec. Expression was quantified using the PCR-based TaqMan® Low Density Arrays. cDNA was added to TaqMan Master mix loaded onto miRNA Arrays A and B. Arrays were run on the Applied Biosystems ViiA™ 7 real-time PCR system and d ata was analyzed using the Expression Suite Software. miRNA expressions on Array A were normalized with hsa-let-7d and those on Array B were normalized using hsa-miR-151-3p. Mock-transfected cells were used as a calibrator.

miRNA target prediction

Target prediction analysis was performed using different programs including TargetScanHuman 6.2 (http://www.targetscan.org/), DIANA-mirPath (http://diana.cslab.ece.ntua.gr/pathways/), the PITA database (http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html), MiRanda (http://www.microrna.org/microrna/home.do), DIANA-microT (http://www.diana.pcbi.upenn.edu/cgi-bin/micro_t.cgi), miRWalk [64],RNA22 (http://cbcsrv.watson.ibm.com/rna22.html), and miRDB (http://mirdb.org/miRDB/). Only predictions of at least three independent programs were included for analysis.

Experimental target validation

Predicted gene targets were confirmed to have altered expression in KLK5-expressing stably transfected clones compared to controls by mRNA microarray expression analysis. PCR analysis using gene-specific probes were used for independent validation. miRNA expressions were assessed by qRT-PCR using TaqMan® probes, as in our recent studies [65].

Pathway enrichment analysis

Pathway enrichment analysis was performed using DIANA miRPath v2.1 [66]. Enrichment analysis software (http://diana.cslab.ece.ntua.gr/) was employed to gain insight into global molecular networks and canonical pathways related to differentially expressed miRNAs between KLK5-expressing and non-expressing MDA-MB-231 cell lines. miRPath identified multiple miRNA target genes using enrichment analysis by comparing each set of miRNA gene targets to all known KEGG pathways. Pathways showing p-value <0.05 were considered significantly enriched pathways after analysis.

Analysis of ECM gene expression by quantitative RT-PCR

Cells were homogenized, and total RNA was extracted according to RNAEasy standard protocol (RNAEasy, Qiagen). RNA purity and quality were assessed using a Bioanalyzer (Agilent Technologies). A260/A230 ratio was over 1.7, and A260/A280 ratio was greater than 2.0. Gene expression was assessed by qRT-PCR using TaqMan® probes and the Human Extracellular Matrix and Adhesion Molecules array (RT2 Profiler PCR Array PAMM-013; SuperArray Biosciences, Frederick, MD). Gene expression was compared between MDA-MB-231transfectants and mock controls. Genes with 2-fold change and p< 0.05 were identified.

miRNA loss of function experiments

Anti-miR-183-5p were used to knockdown miR-183 (Life Technologies). Cells were transfected with either 30nM or 90nM of specific or non-targeting anti-miR using siPORT NeoFX transfection agent (AM4510) for 24h before used for subsequent experiments.

Breast cancer clinical data validation

We validated our results on an independent set from the Cancer Genome Atlas (TCGA) databases [2]. The breast cancer (BRCA) data set was downloaded from TCGA public data portal, and from the cBio Cancer Genomics Portal at the Memorial Sloan-Kettering Cancer Center. Data was analyzed from over 825 breast cancer cases, which comprised tumor mRNA array expression data (n=526) and tumor miRNA array expression data (n=302). For expression data analysis, z-scores or “level 3” normalized data from mRNA and miRNA microarrays were used. Molecular subtype data included luminal B (n=131), luminal A (n=235), basal-like (n=80), and Her-2 enriched (n=58). For microarray analysis, we employed the IlluminaHiSeq expression data set (n=1106) using the Genomics Browser to visualize the data[67].

Abbreviations

KLK: Kallikrein-related peptidase; miRNA, microRNA; TCGA: the cancer genome atlas; ECM: Extracellular matrix; ITGA: Integrin alpha; ITGB: Integrin beta; COL12A1: Collagen alpha-1; PCR: Polymerase chain reaction; qRT-PCR: quantitative Reverse Transcription Polymerase Chain Reaction; KEGG: Kyoto Encyclopedia of Genes and Genomes; 3’ UTR: three prime untranslated region; AGO: Argonaute; MMP: Matrix metalloproteinase; ER: Estrogen receptor

ACKNOWLEDGEMENTS

This work was supported by grants to G.M.Y. from the Canadian Institute of Health Research (MOP-CPT-258846-158579-DLGAR), Kidney Foundation of Canada and Prostate Cancer Canada Movember Discovery Grants, Kidney Cancer Research Network of Canada.

Statement of author contribution

All authors were involved in designing the study, carrying out the experiments, analyzing the data, writing the paper and had final approval of the submitted and published version.

The authors declare that they have no competing interests.

• 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90. https://doi.org/10.3322/caac.20107. [PubMed].
• 2. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70. https://doi.org/10.1038/nature11412. [PubMed].
• 3. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378:1812-1823. https://doi.org/10.1016/S0140-6736(11)61539-0. [PubMed].
• 4. Pasic MD, Samaan S, Yousef GM. Genomic medicine: new frontiers and new challenges. Clin Chem. 2013;59:158-167. https://doi.org/10.1373/clinchem.2012.184622. [PubMed].
• 5. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem. 2002;48:1198-205. [PubMed].
• 6. Yousef GM, Diamandis EP. Expanded human tissue kallikrein family--a novel panel of cancer biomarkers. Tumour Biol. 2002;23:185-92. https://doi.org/10.1159/000064027. [PubMed].
• 7. Avgeris M, Papachristopoulou G, Polychronis A, Scorilas A. Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin Proteomics. 2011;8:5. https://doi.org/10.1186/1559-0275-8-5. [PubMed].
• 8. Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, Diamandis EP. Kallikrein gene downregulation in breast cancer. Br J Cancer. 2004;90:167-72. https://doi.org/10.1038/sj.bjc.6601451. [PubMed].
• 9. Li X, Liu J, Wang Y, Zhang L, Ning L, Feng Y. Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies. Cancer Sci. 2009;100:601-607. https://doi.org/10.1111/j.1349-7006.2009.01090.x. [PubMed].
• 10. Papachristopoulou G, Talieri M, Scorilas A. Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. Tumour Biol. 2013;34:369-378. https://doi.org/10.1007/s13277-012-0558-1. [PubMed].
• 11. Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, Sotiropoulou G. The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. Oncotarget. 2013;. https://doi.org/10.18632/oncotarget.1235. [PubMed].
• 12. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269. https://doi.org/10.1038/nrc1840. [PubMed].
• 13. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1-12. https://doi.org/10.1016/j.ydbio.2006.08.028. [PubMed].
• 14. Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene. 2010;29:2161-2164. https://doi.org/10.1038/onc.2010.59. [PubMed].
• 15. Chow TF, Crow M, Earle T, El-Said H, Diamandis EP, Yousef GM. Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol Chem. 2008;389:731-738. https://doi.org/10.1515/BC.2008.071. [PubMed].
• 16. Pasic MD, Olkhov E, Bapat B, Yousef GM. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there. Biol Chem. 2012;393:319-330. https://doi.org/10.1515/hsz-2011-0273. [PubMed].
• 17. White NM, Bui A, Mejia-Guerrero S, Chao J, Soosaipillai A, Youssef Y, Mankaruos M, Honey RJ, Stewart R, Pace KT, Sugar L, Diamandis EP, Dore J et al. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol Chem. 2010;391:411-423. https://doi.org/10.1515/BC.2010.041. [PubMed].
• 18. White NM, Chow TF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, Mankaruous M, Gabril M, Girgis A, Yousef GM. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer. 2010;102:1244-1253. https://doi.org/10.1038/sj.bjc.6605634. [PubMed].
• 19. White NM, Youssef YM, Fendler A, Stephan C, Jung K, Yousef GM. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol Chem. 2012;393:379-389. https://doi.org/10.1515/hsz-2011-0246. [PubMed].
• 20. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011;15:1593-1602. https://doi.org/10.1111/j.1582-4934.2010.01148.x. [PubMed].
• 21. Elcheva I, Goswami S, Noubissi FK, Spiegelman VS. CRD- BP protects the coding region of betaTrCP1 mRNA from miR-183-mediated degradation. Mol Cell. 2009;35:240-246. https://doi.org/10.1016/j.molcel.2009.06.007. [PubMed].
• 22. Stark TJ, Arnold JD, Spector DH, Yeo GW. High-resolution profiling and analysis of viral and host small RNAs during human cytomegalovirus infection. J Virol. 2012;86:226-235. https://doi.org/10.1128/JVI.05903-11. [PubMed].
• 23. Dostie J, Mourelatos Z, Yang M, Sharma A, Dreyfuss G. Numerous microRNPs in neuronal cells containing novel microRNAs. RNA. 2003;9:180-186. https://doi.org/10.1261/rna.2141503. [PubMed].
• 24. McCarthy JJ, Esser KA, Andrade FH. MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J Physiol Cell Physiol. 2007;293:C451-C457. https://doi.org/10.1152/ajpcell.00077.2007. [PubMed].
• 25. McCarthy JJ, Esser KA. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol (1985 ). 2007;102:306-313. https://doi.org/10.1152/japplphysiol.00932.2006. [PubMed].
• 26. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem. 2005;280:14628-14635. https://doi.org/10.1074/jbc.M408132200. [PubMed].
• 27. O’Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12:201. https://doi.org/10.1186/bcr2484. [PubMed].
• 28. Yousef GM, White NM, Kurlender L, Michael I, Memari N, Robb JD, Katsaros D, Stephan C, Jung K, Diamandis EP. The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. Tumour Biol. 2004;25:221-227. https://doi.org/10.1159/000081384. [PubMed].
• 29. Avgeris M, Papachristopoulou G, Polychronis A, Scorilas A. Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin Proteomics. 2011;8:5. https://doi.org/10.1186/1559-0275-8-5. [PubMed].
• 30. Lee CY, Marzan D, Lin G, Goodison S, Silletti S. alpha2 Integrin-Dependent Suppression of Pancreatic Adenocarcinoma Cell Invasion Involves Ectodomain Regulation of Kallikrein-Related Peptidase-5. J Oncol. 2011;2011:365651. https://doi.org/10.1155/2011/365651. [PubMed].
• 31. Yousef GM, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, Diamandis EP. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate. 2002;51:126-32. https://doi.org/10.1002/pros.10067. [PubMed].
• 32. Planque C, de MM, Guyetant S, Rollin J, Desmazes C, Panel V, Lemarie E, Courty Y. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun. 2005;329:1260-1266. https://doi.org/10.1016/j.bbrc.2005.02.100. [PubMed].
• 33. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, Diamandis EP. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology. 2002;60:714-8. https://doi.org/10.1016/s0090-4295(02)01811-3. [PubMed].
• 34. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Tumour Biol. 2006;27:1-7. https://doi.org/10.1159/000090150. [PubMed].
• 35. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-750. https://doi.org/10.1093/jnci/djp082. [PubMed].
• 36. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012;6:289-297. https://doi.org/10.2147/BTT.S29923. [PubMed].
• 37. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515-527. https://doi.org/10.1016/j.ccr.2006.10.008. [PubMed].
• 38. Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, Lupu F, Lind SE, Ding WQ. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 2011;286:1429-1435. https://doi.org/10.1074/jbc.M110.146530. [PubMed].
• 39. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147-152. https://doi.org/10.1038/nature06487. [PubMed].
• 40. Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Perez-Plasencia C, Del Moral-Hernandez O, Castaneda-Ortiz EJ, Rodriguez-Cuevas S. MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis. Int J Mol Sci. 2012;13:1347-1379. https://doi.org/10.3390/ijms13021347. [PubMed].
• 41. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682-688. https://doi.org/10.1038/nature06174. [PubMed].
• 42. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 2008;68:5004-5008.
• 43. Luo D, Wilson JM, Harvel N, Liu J, Pei L, Huang S, Hawthorn L, Shi H. A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med. 2013;11:57. https://doi.org/10.1186/1479-5876-11-57. [PubMed].
• 44. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138:592-603. https://doi.org/10.1016/j.cell.2009.07.011. [PubMed].
• 45. Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer. 2010;10:502. https://doi.org/10.1186/1471-2407-10-502. [PubMed].
• 46. Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X, Fan Q. miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 2012;30:1013-1020. https://doi.org/10.3892/ijmm.2012.1111. [PubMed].
• 47. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100. https://doi.org/10.1038/nrc727. [PubMed].
• 48. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90:561-565. https://doi.org/10.1038/sj.bjc.6601576. [PubMed].
• 49. van dP, Vloedgraven H, Papapoulos S, Lowick C, Grzesik W, Kerr J, Robey PG. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest. 1997;77:665-675. [PubMed].
• 50. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Targeting of integrin beta1 and kinesin 2alpha by microRNA 183. J Biol Chem. 2010;285:5461-5471. https://doi.org/10.1074/jbc.M109.037127. [PubMed].
• 51. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst. 2002;94:1494-1503. https://doi.org/10.1093/jnci/94.19.1494. [PubMed].
• 52. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997;137:231-245. https://doi.org/10.1083/jcb.137.1.231. [PubMed].
• 53. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 2004;6:159-170. https://doi.org/10.1016/j.ccr.2004.06.025. [PubMed].
• 54. Grigoriadis A, Mackay A, Reis-Filho JS, Steele D, Iseli C, Stevenson BJ, Jongeneel CV, Valgeirsson H, Fenwick K, Iravani M, Leao M, Simpson AJ, Strausberg RL et al. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res. 2006;8:R56. https://doi.org/10.1186/bcr1604. [PubMed].
• 55. Adriance MC, Inman JL, Petersen OW, Bissell MJ. Myoepithelial cells: good fences make good neighbors. Breast Cancer Res. 2005;7:190-197. https://doi.org/10.1186/bcr1286. [PubMed].
• 56. Turner NA, O’Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 2005;19:804-806. https://doi.org/10.1096/fj.04-2852fje. [PubMed].
• 57. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182-186. https://doi.org/10.1038/nm982. [PubMed].
• 58. Ramani VC, Kaushal GP, Haun RS. Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains. Biochim Biophys Acta. 2011;1813:1525-1531. https://doi.org/10.1016/j.bbamcr.2011.05.007. [PubMed].
• 59. Corthorn J, Rey S, Chacon C, Valdes G. Spatio-temporal expression of MMP-2, MMP-9 and tissue kallikrein in uteroplacental units of the pregnant guinea-pig (Cavia porcellus). Reprod Biol Endocrinol. 2007;5:27. https://doi.org/10.1186/1477-7827-5-27. [PubMed].
• 60. Yoon H, Blaber SI, Li W, Scarisbrick IA, Blaber M. Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases. Biol Chem. 2013;394:137-147. https://doi.org/10.1515/hsz-2012-0249. [PubMed].
• 61. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer. 2009;9:188. https://doi.org/10.1186/1471-2407-9-188. [PubMed].
• 62. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012;12:613-626. https://doi.org/10.1038/nrc3318. [PubMed].
• 63. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol. 1998;143:547-560. https://doi.org/10.1083/jcb.143.2.547. [PubMed].
• 64. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk--database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform. 2011;44:839-847. https://doi.org/10.1016/j.jbi.2011.05.002. [PubMed].
• 65. Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, Girgis H, Von B, I, Bjarnason GA, Yousef GM. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis. 2013;34:2231-2239. https://doi.org/10.1093/carcin/bgt184. [PubMed].
• 66. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics. 2009;25:1991-1993. https://doi.org/10.1093/bioinformatics/btp299. [PubMed].
• 67. Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T. The UCSC Cancer Genomics Browser. Nat Methods. 2009;6:239-240. https://doi.org/10.1038/nmeth0409-239. [PubMed].
• 68. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.. 2009;6:239-240.